BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BC Week In Review | Dec 5, 2011
Company News

Amgen autoimmune news

Amgen said the U.S. Patent and Trademark Office issued a patent covering the fusion protein that constitutes autoimmune drug Enbrel etanercept. The patent, which expires in 2028, describes the non-soluble proteins and soluble or insoluble...
BC Extra | Nov 24, 2011
Company News

PTO issues Enbrel patent

Amgen Inc. (NASDAQ:AMGN) said the U.S. Patent and Trademark Office issued a patent covering the fusion protein that constitutes autoimmune drug Enbrel etanercept. The patent, which expires in 2028, describes the non-soluble proteins and soluble...
BC Week In Review | Jun 20, 2011
Company News

Hanwha Chemical Corp., Merck deal

Hanwha partnered with Merck to develop and commercialize Hanwha's biosimilar of autoimmune drug Enbrel etanercept. The compound, HD203 , is in a Korean Phase III trial to evaluate its equivalence to Enbrel in rheumatoid arthritis (RA)....
BC Extra | Jun 13, 2011
Company News

Merck gains rights to Enbrel biosimilar

Hanwha Chemical Corp. (KSE:09830) partnered with Merck & Co. Inc. (NYSE:MRK) to develop and commercialize Hanwha's biosimilar version of autoimmune drug Enbrel etanercept. The compound, HD203, is in a Korean Phase III trial to evaluate...
Items per page:
1 - 5 of 5